Clinical Trials/NCT05242432

NCT05242432

Terminated

Phase 3

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Efficacy, Safety, Reactogenicity, and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Japanese Adults Aged 60 Years and Older, and Safety, Reactogenicity, and Immunogenicity of the Vaccine in Japanese Adults Aged 20 to 59 Years at High-risk of RSV Disease

Janssen Pharmaceutical K.K.30 sites in 1 country2,192 target enrollmentApril 1, 2022

ConditionsRespiratory Syncytial Virus Prevention

InterventionsAd26/protein preF RSV Vaccine Placebo

Overview

Phase: Phase 3
Intervention: Ad26/protein preF RSV Vaccine
Conditions: Respiratory Syncytial Virus Prevention
Sponsor: Janssen Pharmaceutical K.K.
Enrollment: 2192
Locations: 30
Primary Endpoint: Cohort 1: Number of Participants with First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) confirmed Respiratory Syncytial Virus (RSV) Mediated-lower Respiratory Tract Disease (LRTD) Over one RSV Season
Status: Terminated
Last Updated: 11 months ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of the study is to evaluate the efficacy of study vaccine in the prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-confirmed RSV mediated- lower Respiratory Tract Disease (LRTD) over one RSV season when compared to placebo in adults aged 60 years and above and to demonstrate the non-inferiority of the vaccine in high-risk adults aged 20 to 59 years versus in adults aged 60 years and older in terms of humoral immune response.

Registry

clinicaltrials.gov

Start Date

April 1, 2022

End Date

March 20, 2023

Last Updated

11 months ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Janssen Pharmaceutical K.K.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•For Participants in Cohort 1 only
•Must be greater than or equal to (\>=60) years old on the day of signing the informed consent form (ICF) and expected to be available for the duration of the study
•Before randomization, a participant must be postmenopausal (postmenopausal state is defined as no menses for 12 months without an alternative medical cause); and not intending to conceive by any methods
•Participants may have underlying illnesses such as hypertension, congestive heart failure (CHF), Chronic obstructive pulmonary disease (COPD), type 2 diabetes, hyperlipoproteinemia, or hypothyroidism, as long as their symptoms and signs are stable and medically controlled in the judgement of the investigator at the time of vaccination, and these conditions receive routine follow-up by the participant's healthcare provider
•For Participants in Cohort 2 only
•Must be aged 20 to 59 years (inclusive) on the day of signing the ICF and expected to be available for the duration of the study
•Has an existing chronic heart or lung condition, without hospitalizations or major medication class change (that is, new or stopped medications) within 30 days prior to screening
•Participant may have other underlying illnesses as long as their symptoms and signs are stable at the time of vaccination, and these conditions receive routine follow-up by the participant's healthcare provider

Exclusion Criteria

•Has a serious clinically unstable condition like, (example, end-stage renal disease with or without dialysis, clinically unstable cardiac disease), Alzheimer's disease, or any other condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise well-being) or that could prevent or limit the protocol-specified assessments
•History of malignancy within 5 years before screening or revaccination not in the following categories: a. participants with squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix may be enrolled at the discretion of the investigator; b. participants with a history of malignancy within 5 years, which is considered cured with minimal risk of recurrence per investigator's judgement, can be enrolled
•Had major surgery (example, major cardiopulmonary or abdominal operations) as per the investigator's judgment within 4 weeks before vaccination, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to participate in the study
•Has an acute illness (including acute respiratory illnesses) or body temperature of \>=38.0 degree Celsius (ºC) (\>=100.4 Fahrenheit \[ºF \] within 24 hours prior to administration of study vaccine)
•Has had major psychiatric illness and/or drug or alcohol abuse which in the investigator's opinion would compromise the participant's safety and/or compliance with the study procedures

Arms & Interventions

Cohort (C)1 Group (G)1: Adults, 60 years and older (Ad26/protein preF RSV Vaccine)

Participants will receive a single intramuscular (IM) injection of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26/protein preF RSV) vaccine on Day 1.

Intervention: Ad26/protein preF RSV Vaccine

C1 G2: Adults, 60 years and older (Placebo)

Participants will receive a single IM injection of matching placebo on Day 1.

Intervention: Placebo

C2 G3: Adults Aged 20 to 59 years at High-risk of Severe RSV Disease (Ad26/protein preF RSV Vaccine)

Participants will receive a single IM injection of Ad26/protein preF RSV vaccine on Day 1.

Intervention: Ad26/protein preF RSV Vaccine

C2 G4: Adults Aged 20 to 59 years at High-risk of Severe RSV Disease (Placebo)

Participants will receive a single IM injection of matching placebo on Day 1.

Intervention: Placebo

Outcomes

Primary Outcomes

Cohort 1: Number of Participants with First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) confirmed Respiratory Syncytial Virus (RSV) Mediated-lower Respiratory Tract Disease (LRTD) Over one RSV Season

Time Frame: Until end of RSV season (up to 11.5 months)

Number of participants with first occurrence of RT-PCR confirmed RSV Mediated LRTD over one RSV season will be reported.

Cohort 2: Neutralizing Antibody Titers Against RSV A Strain as Measured by Virus Neutralizing Antibody (VNA) Assay

Time Frame: Day 15

Neutralizing antibody titers against RSV A strain as measured by VNA Assay will be reported.

Secondary Outcomes

Cohort 1 (Immuno Subset): Neutralizing Antibody Titers Against RSV A Strain(Day 1, 15, 85, and 169)
Cohort 1 (Immuno Subset) and 2: RSV A F protein in pre-fusion form Binding Antibodies as Assessed by Enzyme linked Immuno Sorbent Assay (ELISA)(Cohort 1: Day 1, 15, 85, and 169; Cohort 2: 14 days after vaccination (Day 15))
Cohorts 1 and 2: Number of Participants with Serious Adverse Events (SAEs)(Cohort 1: Up to 6 months after vaccination or end of RSV season, whichever comes later (up to 11.5 months); Cohort 2: Up to 6 months after vaccination)
Cohort 1 (Safety Subset) and Cohort 2: Number of Participants with Solicited Local Adverse Events (AEs) After Vaccination(7 Days after vaccination (Day 1 to Day 8))
Cohort 1: Number of Participants with First Occurrence of RT-PCR Confirmed RSV-mediated Acute Respiratory Infection (ARI) Over one RSV Season(Until end of RSV season (up to 11.5 months))
Cohort 1 (Safety Subset) and Cohort 2: Number of Participants with Solicited Systemic AEs After Vaccination(7 Days after vaccination (Day 1 to Day 8))
Cohort 1 (Safety Subset) and Cohort 2: Number of Participants with Unsolicited AEs After Vaccination(28 days after vaccination (Day 1 to Day 29))
Cohort 2: Neutralizing Antibody Titers Against RSV A Strain iso RSV A2 as Measured by VNA Assay in terms of Seroresponse rate(14 days after vaccination (Day 15))
Cohorts 1 and 2: Number of Participants with Adverse Events of Special Interest (AESIs)(Cohort 1: Up to 6 months after vaccination or end of RSV season, whichever comes later (up to 11.5 months); Cohort 2: Up to 6 months after vaccination)